FDA removes long-standing warning from hormone-based menopause drugs

"Hormone-based drugs used to treat hot flashes and other menopause symptoms will no longer carry a bold warning label about stroke, heart attack, dementia and other serious risks, the Food and Drug Administration announced Monday. U.S. health officials said they will remove the boxed warning from more than 20 pills, patches and creams containing hormones like estrogen and progestin, which are approved to ease disruptive symptoms like night sweats."

"The change has been supported by some doctors including FDA Commissioner Marty Makary, who has called the current label outdated and unnecessary. But some doctors worried that the process that led to the decision was flawed. Health officials explained the move by pointing to studies suggesting hormone therapy has few risks when started before age 60 or within 10 years of menopause symptoms. We're challenging outdated thinking and recommitting to evidence-based medicine that empowers rather than restricts, Health Secretary Robert F. Kennedy Jr. said in introducing the update."

"The 22-year-old FDA warning advised doctors that hormone therapy can increase the risk of blood clots, heart problems and other health issues, citing data published more than 20 years ago. Many doctors and pharmaceutical companies have called for removing or revising the label, which they say discourages prescriptions and scares off women who could benefit. Dr. Steven Fleischman, president of the American College of Obstetricians and Gynecologists, said the warnings have created a lot of hesitancy among patients."

FDA will remove the boxed warning from more than 20 hormone-containing pills, patches and creams used to treat menopause symptoms such as hot flashes and night sweats. Health officials cited studies indicating hormone therapy carries few risks when initiated before age 60 or within 10 years of menopause. Supporters, including some doctors and FDA Commissioner Marty Makary, say the existing warning is outdated and deters beneficial treatment. Critics argue the decision-making process lacked a transparent, advisory review and express concern about potential safety implications. The 22-year-old warning had cited increased risks of blood clots, heart problems and other health issues.

Read at www.mercurynews.com